Tamoxifen is a selective estrogen receptor modulator. An article about new indications for Lilly's osteoporosis drug Evista described tamoxifen as an aromatase inhibitor. Additionally, Lilly's arzoxifene is in Phase III studies for prevention of invasive breast cancer and treatment of osteoporosis - Phase III studies for the treatment of metastatic breast cancer are not underway (1"The Pink Sheet" Sept. 24, 2007, p. 16)...
You may also be interested in...
FDA's approval of Lilly's osteoporosis drug Evista for two preventative cancer treatment indications expands the drug's market into the oncology field, while placing it at odds with competing osteoporosis products because of new risk labeling
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.